Dr Ilias Goranitis MSc, PhD

Institute of Applied Health Research
Honorary Research Fellow

Contact details

Telephone: +44 (0)121 414 7074
Fax: +44 (0)121 414 8969
Email: i.goranitis@bham.ac.uk
Twitter: @IliasGoranitis

Address: Health Economics Unit
IOEM Building
College of Medical and Dental Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Ilias Goranitis is a senior health economics research fellow within the Centre for Health Policy and the Health Economics Unit at the University of Melbourne, Australia. Dr Goranitis specialises in the economic evaluation and outcome valuation of genomic technologies. His main applied and methodological work focuses on exploring the cost-effectiveness of genomic technologies as well as the individual preferences for genomic testing using health economic and discrete choice modelling.

Dr Goranitis was a research fellow (2012-2017) and deputy director of teaching (2014-2017) on health economics at the University of Birmingham. Now he works closely with the Health Economics Unit across different projects, including: AIMS, PRISM, and MIFEMISO trials and the Shifting Shapes study in collaboration with the Health Services Management Centre at the University of Birmingham.

Qualifications

PhD in Healthcare Management and Evaluation, University of Athens, 2013
MSc in International Health Policy and Economics, London School of Economics and Political Science (LSE), 2012
MSc in Healthcare Management and Evaluation, University of Athens, 2007

Biography

Ilias Goranitis is a senior health economics research fellow at the University of Melbourne and specialises in the economic evaluation and outcome valuation of genomic technologies. His main applied and methodological work focuses on exploring the cost-effectiveness of genomic technologies as well as the individual preferences for genomic testing using health economic and discrete choice modelling. Dr Goranitis is jointly working between the Centre for Health Policy at the University of Melbourne and the Australian and Melbourne Genomic Health Alliances at the Murdoch Children’s Research Institute (MCRI), aiming to provide health economic evidence for the implementation of genomic medicine that will inform state and federal government policy in Australia. Prior to joining the University of Melbourne, Dr Goranitis was a research fellow and deputy director of teaching on health economics at the University of Birmingham. Dr Goranitis has been a successful co-applicant in research grants from the NIHR HTA and the Department of Health in the UK (Calibre trial, Mifemiso trial, PPH study, Shifting shapes study) worth £5 million, and he has been a health economics investigator in large NIHR-funded health technology assessments (Trapeze trial, Prism trial and BUS study) and research for patient benefit (SBNT study) programmes as well as a large multinational trial funded by the MRC, the Wellcome Trust, and the Department for International Development in the UK (AIMS trial). His work has been published in high impact journals, such as Health Technology Assessment, JAMA oncology, Medical Decision Making, PharmacoEconomics, Value in Health, Plos ONE, Quality of Life Research, and he has contributed to a book on Mental Health Economics published by Springer International. Dr Goranitis has collaborated on research with the National Institute for Health and Care Excellence (NICE) in the UK and has offered health economics advice as part of the NIHR Research Design Service (West Midlands). He has significant experience in teaching and leading the delivery of health economics related subjects to undergraduate economics and postgraduate health economics students. Dr Goranitis holds honorary appointments with the MCRI and the University of Birmingham and is an alumnus of the London School of Economics and the University of Athens.

Teaching

BSc Economics
- Cost-benefit analysis
MSc Health Economics and Health Policy; MSc Health Economics and Econometrics; MSc Public Health
- Seminars
  - Statistics
  - Modelling for health economics
- Lectures
  - Introduction to health economics
  - Health systems
  - Market failures
  - Supplier-induced demand and incentive issues
  - Policy responses to moral hazard
  - Health systems and global health

Postgraduate supervision

Inquiries from students on the following subjects are welcome:

Micro-level:

- Economic evaluation of health and social care interventions
- Applications of the capability and sufficient capability approach in health economic evaluations
- Measurement and valuation of health benefits
- Multiple imputation of missing trial data

Macro-level
- Impacts of economic recessions on health
- Health inequalities
- Health financing

Research

Decision-analytic modelling
Discrete choice modelling
Genomics
Health economic evaluation
Outcome measurement and valuation

Research groups and centres:

https://mspgh.unimelb.edu.au/centres-institutes/centre-for-health-policy/research-group/health-economics

Other activities

Member of:

International Health Economics Association (iHEA)
Health Economists’ Study Group (HESG)

Publications

Peak, J., Goranitis, I., Day, E., Copello, A., Freemantle, N. and Frew, E., 2018. Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP. Health and quality of life outcomes, 16(1), p.106.

Andronis, L., Goranitis, I., Bayliss, S. and Duarte, R., 2018. Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review. PharmacoEconomics, 36(3), p.301.

Lissauer, D., Wilson, A., Daniels, J., Middleton, L., Bishop, J., Hewitt, C., Merriel, A., Weeks, A., Mhango, C., Mataya, R., Taulo, F. et al., 2018. Prophylactic antibiotics to reduce pelvic infection in women having miscarriage surgery–The AIMS (Antibiotics in Miscarriage Surgery) trial: study protocol for a randomized controlled trial. Trials, 19(1), p.245.

Day, E., Copello, A., Seddon, J.L., Christie, M., Bamber, D., Powell, C., Bennett, C., Akhtar, S., George, S., Ball, A., Frew, E., Goranitis, I., and Freemantle, N. 2018. A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services. BMC psychiatry, 18(1), p.8.

Goranitis I., Daley AJ, Stokes-Lampard H, Roalfe AK, Bellanca L and Jowett S. Aerobic exercise for vasomotor menopausal symptoms: a cost-utility analysis based on the Active Women trial. Accepted in PLoS ONE.

Coast J., Mitchell, P., Goranitis I., Ethics and values in welfarism and extra-welfarism IN: Razzouk D. Mental Health Economics - The Costs and Benefits of Psychiatric Care. Springer International Publishing. DOI 10.1007/978-3-319-55266-8; Hardcover ISBN 978-3-319-55265-1; eBook ISBN 978-3-319-55266-8.

Goranitis I., Coast J., Day E., Copello A., Freemantle N., and Frew E. Maximising health or sufficient capability in economic evaluation? A methodological experiment of treatment for drug addiction. Medical Decision Making: an international journal of the Society for Medical Decision Making 37.5 (2017): 498.

Rachaneni S., McCooty S., Middleton L.J., Brookes V.L., Daniels J.P., Coomarasamy A., Verghese T., Balogun M., Goranitis I., Barton P., Roberts T.E., Deeks J.J., Latthe P. Accuracy and economic evaluation of Bladder Ultrasound in the diagnosis of Detrusor Overactivity: a study to evaluate if ultrasound can reduce the need for urodynamics. NIHR Health Technology Assessment (HTA). 20.7 (2016): 1-150.

Goranitis I., Barton P., Middleton L., Deeks J.J., Daniels J., Coomarasamy A., Rachaneni S., McCooty S., Verghese T., Latthe P., and Roberts T.E. Testing and treating women with persistent symptoms of overactive bladder or mixed urinary incontinence: A model-based economic evaluation. PLoS ONE 11(8): e0160351. doi:10.1371/journal.pone.0160351(2016).

Latthe P.M., Middleton L., Rachaneni S., McCooty S., Daniels J., Coomarasamy A., Balogun M., Duckett J., Thakar R., Goranitis I., Roberts TE, and Deeks J.J. Ultrasound bladder wall thickness and detrusor overactivity: a multicentre test accuracy study. BJOG: An International Journal of Obstetrics & Gynaecology (2017).

James N., Pirrie S., Pope A., Barton D., Andronis L., Goranitis I., Billingham L. et al. TRAPEZE: A randomised controlled trial of the clinical and cost effectiveness of chemotherapy with zoledronic acid, strontium-89 or both, in men with bony metastatic castrate refractory prostate cancer. NIHR Health Technology Assessment (HTA). 20.53 (2016): 1-324.

Andronis L., Goranitis I. et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. British Journal of Urology International (BJUI). DOI: 10.1111/bju.13549 (2016).

James N., Pirrie S., Pope A., Barton D., Andronis L., Goranitis I. et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel with strontium-89, zoledronic acid, neither, or both. JAMA Oncol. 2.4(2016):493-499. doi:10.1001/jamaoncol.2015.5570.

Goranitis I., Coast J., Day E., Copello A., Freemantle N., Seddon J., Bennett C., Frew E. Measuring health and broader wellbeing benefits in the context of drug addiction: the psychometric performance of the ICECAP-A and EQ-5D-5L. Value in Health. 19.6 (2016): 820–828. doi:10.1016/j.jval.2016.04.010.

Goranitis I., Coast J., Al-Janabi H., Latthe P., and Roberts T.E. The validity and responsiveness of the ICECAP-A capability-wellbeing measure in women with overactive bladder symptoms. Quality of Life Research. 25.8 (2016): 2063–2075. doi 10.1007/s11136-015-1225-y.

Frempong S., Goranitis I., and Oppong R. Economic evaluation alongside factorial trials: a systematic review of empirical studies. Expert Review of Pharmacoeconomics & Outcomes Research. 15.5 (2015): 801-811.

Goranitis, I., Coast J., and Al-Janabi H. An investigation into the construct validity of the Carer Experience Scale (CES). Quality of Life Research (2014): 1-10.

Goranitis, I., Siskou O., and Liaropoulos L. Health policy making under information constraints: An evaluation of the policy responses to the economic crisis in Greece. Health Policy 117.3 (2014): 279-284.

Liaropoulos L. and Goranitis I. Health care financing and the sustainability of health systems. International Journal for Equity in Health. 14.1 (2015): 80. DOI 10.1186/s12939-015-0208-5.

View all publications in research portal